Frontiers in Medical Technology specialty section Regulatory Affairs aims to bridge the gap between the regulatory requirements for the registration of medicines, combination products and medical devices, Health Technology Assessment and reimbursement. In the last decade there has been an effort to better align such requirements for efficacy, effectiveness, cost-effectiveness, benefits, toxicity and safety. Regulatory Affairs welcomes papers on both regulatory issues relating to new medical technologies as well as Health Technology Assessment.
Frontiers specialty section Regulatory Affairs aims to bridge the gap between the regulatory requirements for the registration of medicines, combination products and medical devices, Health Technology Assessment and reimbursement. In the last decade there has been an effort to better align such requirements for efficacy, effectiveness, cost-effectiveness, benefits, toxicity and safety. Regulatory Affairs welcomes papers on both regulatory issues relating to new medical technologies as well as Health Technology Assessment. Topics may concern the whole spectra of trial design to real-world evidence, the use of intermediate to final endpoints, quality-of-life estimation to costing, numbers needed to treat to cost per quality-adjusted life-year and benefit/harm to cost-utility analysis.
Requirements for market authorizations and reimbursements all face specific and common challenges, both for conventional medicines as well as test, aids and appliances and new highly-specialized technologies, such as cell and gene therapies, medicines for ultra-rare diseases, new classes of vaccines, immunotherapies and others. Papers on all these issues are also welcomed, both applied and methodological.
Alongside practical issues for regulation, Regulatory Affairs aims to enhance methodologies and related discussions. These can be in the areas of survival analysis, extrapolations, propensity scoring, quality of life-measurement, cost-effectiveness analysis, probabilistic and uncertainty analyses, ethical philosophies and economic theories. Overall, Regulatory Affairs aims to bring the worlds of technologies' marketing authorization and technologies’ reimbursement closer together, ultimately benefiting the patients with rapidly available, effective, safe, affordable and cost-effective treatments within sustainable health-care systems.
Indexed in: Google Scholar, DOAJ, CrossRef, CLOCKSS
PMCID: NA
Regulatory Affairs welcomes submissions of the following article types: Brief Research Report, Case Report, Classification, Clinical Trial, Community Case Study, Correction, Curriculum, Instruction, and Pedagogy, Data Report, Editorial, General Commentary, Hypothesis and Theory, Methods, Mini Review, Opinion, Original Research, Perspective, Policy and Practice Reviews, Policy Brief, Review, Specialty Grand Challenge, Study Protocol, Systematic Review and Technology and Code.
All manuscripts must be submitted directly to the section Regulatory Affairs, where they are peer-reviewed by the Associate and Review Editors of the specialty section.
Frontiers Editorial Office
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
Frontiers Support
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
support@frontiersin.org
Avenue du Tribunal Fédéral 34
CH – 1005 Lausanne
Switzerland
Tel +41(0)21 510 17 40
Fax +41 (0)21 510 17 01
For all queries regarding manuscripts in Review and potential conflicts of interest, please contact medicaltechnology.editorial.office@frontiersin.org
For queries regarding Research Topics, Editorial Board applications, and journal development, please contact medicaltechnology@frontiersin.org
Tel +41(0)21 510 17 10
Fax +41 (0)21 510 17 01
For technical issues, please visit our Frontiers Help Center, or contact our IT HelpDesk team at support@frontiersin.org